Skip to main content

ATPgammaS enhances the production of inflammatory mediators

Adenosine 5'-triphosphate (ATP) affects multiple intra- and extracellular processes, including vascular tone and immune responses. Microvascular endothelial cells (EC) play a central role in inflammation by recruitment of inflammatory cells from blood to tissues.

We hypothesized that ATP (secreted by neurons and/or released after perturbation of cutaneous cells) may influence secretion of inflammatory messengers by dermal microvascular EC through actions on purinergic P2 receptors. Addition of the hydrolysis-resistant ATP analogue, adenosine 5'-O-(3-thiotriphosphate) (ATPgammaS), to subconfluent cultures of the human microvascular endothelial cell-1 (HMEC-1) cell line led to a dose- and time-dependent increase in release of IL-6, IL-8, monocyte chemoattractant protein-1, and growth-regulated oncogene alpha.

Both ATPgammaS-induced release and basal production of these proteins were significantly inhibited by the purinergic antagonists pyridoxal-5'-phosphate-6-azophenyl-2',5'-disulfonic acid (PPADS), pyridoxal-5'-phosphate-6(2'-naphthylazo-6-nitro-4',8'-disulfonate), and suramin. ATPgammaS increased expression of intercellular adhesion molecule-1 (ICAM-1), whereas suramin and PPADS decreased both ATPgammaS-induced and basal ICAM-1 expression.

Using PCR, we found that HMEC-1 strongly express mRNA for the P2X(4), P2X(5), P2X(7), P2Y(2), and P2Y(11) receptors and weakly express mRNA for P2X(1) and P2X(3) receptors. Purinergic nucleotides may mediate acute inflammation in the skin and thus contribute to physiological and pathophysiological inflammation. For example, ATP may contribute to both the vasodilation and the inflammation associated with rosacea.


"ATPgammaS enhances the production of inflammatory mediators by a human dermal endothelial cell line via purinergic receptor signaling.
Seiffert K, Ding W, Wagner JA, Granstein RD
J Invest Dermatol. 2006 May ; 126(5): 1017-27 (Hubmed.org)



Highlight :
Treatment Of Rosacea | Acne Rosacea Antibiotic | Acne Rosacea | Rosacea Creams

Popular posts from this blog

1971 Innocenti Mini Cooper

1971 Innocenti Mini Cooper " An original Austin Mini Cooper. Not that strange, except I'm 6'4" and 260lbs. Would look kinda funny gettin in and out. _____ " Search Suggestion mk1forum net • view topic early navy blue 1275 gt seats Austin Cooper 998 Mk II 1969 Austin Mini Clubman 1970 Morris Mini Clubman 1275 GT 1971 Cooper S mk III replica 1971 Innocenti Cooper 1300 Export 1974 Morris mini 850 1976. http://mk1-forum.net/viewtopic.php?f=8&t=116 innocenti mini cooper flickr photo sharing After 1971 the production of Mini Coopers were continued in license in Italy by Innocenti as the Innocenti Mini Cooper 1300 and in Spain by Authi (Automoviles de Turismo Hispano . http://www.flickr.com/photos/ilmungo/26099568/ austin mini coopers for sale austin mini cooper classifieds In 1971, the 1275 cc Mini Cooper S was discontinued in the UK, leaving the Mini 1275GT as the only sporting Mini on sale for the rest of the decade. Innocenti in Italy . ht...
Read more

Azelaic acid in the treatment of papulopustular rosacea

To evaluate the clinical efficacy of topical 20% azelaic acid cream and 15% azelaic acid gel compared with their respective vehicles and metronidazole gel in the treatment of papulopustular rosacea . DATA SOURCES: Electronic searches of MEDLINE, EMBASE, BIOSIS, and SciSearch through July or August 2004 and the Cochrane Central Register of Controlled Trials through 2004 (issue 3). We performed hand searches of reference lists, conference proceedings, and clinical trial databases. Experts in rosacea and azelaic acid were contacted. STUDY SELECTION: Randomized controlled trials involving topical azelaic acid (cream or gel) for the treatment of rosacea compared with placebo or other topical treatments. Two authors independently examined the studies identified by the searches. Ten studies were identified, of which 5 were included (873 patients). DATA EXTRACTION: Two authors independently extracted data from the included studies, then jointly assessed methodological quality using a quality a...
Read more

Management of benign skin lesions commonly affecting the face: actinic keratosis, seborrheic keratosis, and rosacea.

Curr Opin Otolaryngol Head Neck Surg. 2009 May 21; Brodsky JPURPOSE OF REVIEW: Patients commonly present to the otolaryngologist for management of benign facial lesions. It is important to be able to both recognize these lesions and offer patients the most effective therapies currently available. Advances in the understanding and management of three of the more common benign skin lesions affecting the face will be addressed in this review, with a particular emphasis on the most current therapeutic options for each lesion. RECENT FINDINGS: Actinic keratosis can now be treated with photodynamic therapy or with many topical agents, as alternatives to traditional surgical techniques. Seborrheic keratosis, as well as actinic keratosis and rosacea, are now often treated with laser therapy. In addition, rosacea management now includes nonantimicrobial topical agents, such as azelaic acid, and a wider armamentarium of systemic agents. SUMMARY: An understanding of these options will allow the ...
Read more